Hans Kaspar Binz
#162,064
Most Influential Person Now
Researcher ORCID ID = 0000-0003-0702-2280
Hans Kaspar Binz's AcademicInfluence.com Rankings
Hans Kaspar Binzcomputer-science Degrees
Computer Science
#9410
World Rank
#9884
Historical Rank
Computational Linguistics
#2268
World Rank
#2291
Historical Rank
Machine Learning
#4110
World Rank
#4159
Historical Rank
Artificial Intelligence
#4450
World Rank
#4511
Historical Rank
Download Badge
Computer Science
Hans Kaspar Binz's Degrees
- PhD Computer Science ETH Zurich
- Masters Computer Science University of Zurich
- Bachelors Computer Science University of Zurich
Similar Degrees You Can Earn
Why Is Hans Kaspar Binz Influential?
(Suggest an Edit or Addition)Hans Kaspar Binz's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Engineering novel binding proteins from nonimmunoglobulin domains (2005) (636)
- High-affinity binders selected from designed ankyrin repeat protein libraries (2004) (630)
- High-affinity binders selected from designed ankyrin repeat protein libraries (2004) (630)
- Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. (2003) (509)
- Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. (2003) (509)
- Comprehensive survey of proteins targeted by chloroplast thioredoxin (2001) (395)
- Shared idiotypic determinants on B and T lymphocytes reactive against the same antigenic determinants. I. Demonstration of similar or identical idiotypes on IgG molecules and T-cell receptors with specificity for the same alloantigens (1975) (332)
- Designed to be stable: Crystal structure of a consensus ankyrin repeat protein (2003) (273)
- Designed to be stable: Crystal structure of a consensus ankyrin repeat protein (2003) (273)
- DARPins: a new generation of protein therapeutics. (2008) (222)
- DARPins: a new generation of protein therapeutics. (2008) (222)
- Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. (2010) (221)
- Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. (2010) (221)
- Antigen-binding, idiotypic T-lymphocyte receptors. (1977) (213)
- Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display (2006) (204)
- Two Different VH Gene Products Make Up the T‐Cell Receptors (1976) (174)
- Folding and unfolding mechanism of highly stable full-consensus ankyrin repeat proteins. (2008) (174)
- Shared Idiotypic Determinants on B and T Lymphocytes Reactive Against the Same Antigenic Determinants (1976) (145)
- Engineered proteins as specific binding reagents. (2005) (143)
- A novel strategy to design binding molecules harnessing the modular nature of repeat proteins (2003) (142)
- A novel strategy to design binding molecules harnessing the modular nature of repeat proteins (2003) (142)
- Cell surface display of recombinant proteins on Staphylococcus carnosus (1995) (136)
- Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. (2007) (133)
- Designing repeat proteins: modular leucine-rich repeat protein libraries based on the mammalian ribonuclease inhibitor family. (2003) (129)
- Designing repeat proteins: modular leucine-rich repeat protein libraries based on the mammalian ribonuclease inhibitor family. (2003) (129)
- Intracellular Kinase Inhibitors Selected from Combinatorial Libraries of Designed Ankyrin Repeat Proteins* (2005) (128)
- Intracellular Kinase Inhibitors Selected from Combinatorial Libraries of Designed Ankyrin Repeat Proteins* (2005) (128)
- Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. (1997) (127)
- Shared idiotypic determinants on B and T lymphocytes reactive against the same antigenic determinants. II. Determination of frequency and characteristics of idiotypic T and B lymphocytes in normal rats using direct visualization (1975) (121)
- Designed armadillo repeat proteins as general peptide-binding scaffolds: consensus design and computational optimization of the hydrophobic core. (2008) (120)
- Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. (2013) (115)
- Repopulation of the atrophied thymus in diabetic rats by insulin-like growth factor I. (1990) (108)
- Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein. (1991) (103)
- Consensus Design of Repeat Proteins (2004) (95)
- Consensus Design of Repeat Proteins (2004) (95)
- T-cell idiotypes are linked to immunoglobulin heavy chain genes (1976) (94)
- DARPins: a true alternative to antibodies. (2007) (90)
- Specific transplantation tolerance induced by autoimmunization against the individual's own, naturally occurring idiotypic, antigen-binding receptors (1976) (87)
- Hydrophobicity engineering to increase solubility and stability of a recombinant protein from respiratory syncytial virus. (1995) (84)
- Expression of recombinant proteins on the surface of the coagulase-negative bacterium Staphylococcus xylosus (1992) (81)
- Epitope mapping by chemical modification of free and antibody-bound protein antigen. (1987) (79)
- Allosteric inhibition of aminoglycoside phosphotransferase by a designed ankyrin repeat protein. (2005) (77)
- Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. (2014) (75)
- Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications (2012) (72)
- Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications (2012) (72)
- Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries. (2006) (69)
- Cell-surface display of heterologous epitopes on Staphylococcus xylosus as a potential delivery system for oral vaccination. (1993) (68)
- Shared idiotypic determinants on B and T lymphocytes reactive against the same antigenic determinants. III. Physical fractionation of specific immunocompetent T lymphocytes by affinity chromatography using anti-idiotypic antibodies (1975) (66)
- Induction of specific transplantation immune reactions using anti- idiotypic antibodies (1978) (63)
- Specific unresponsiveness to transplantation antigens induced by auto-immunisation with syngeneic, antigen-specific T lymphoblasts (1976) (63)
- Inhibition of Local Graft-versus-Host Reaction by Anti-Alloantibodies (1973) (63)
- Shared Idiotypic Determinants on B and T Lymphocytes Reactive Against the Same Antigenic Determinants (1975) (63)
- Mutational analysis of the interaction between albumin‐binding domain from streptococcal protein G and human serum albumin (2002) (63)
- Surface display of the cholera toxin B subunit on Staphylococcus xylosus and Staphylococcus carnosus (1997) (62)
- Antigen-binding, idiotypic receptors from T lymphocytes: an analysis of their biochemistry, genetics, and use as immunogens to produce specific immune tolerance. (1977) (61)
- Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide. (1997) (60)
- Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A (2013) (59)
- Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na. (1997) (59)
- Fusions to the cholera toxin B subunit: influence on pentamerization and GM1 binding. (1997) (56)
- Induction of specific immune unresponsiveness with purified mixed leukocyte culture-activated T lymphoblasts as autoimmunogen. III. Proof for the existence of autoanti-idiotypic killer T cells and transfer of suppression to normal syngeneic recipients by T or B lymphocytes (1978) (54)
- Successful induction of specific tolerance to transplantation antigens using autoimmunisation against the recipient's own natural antibodies (1976) (52)
- Glycosylimidate, 10. Glycosylphosphate aus Glycosyl(trichloracetimidaten) (1984) (48)
- Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches (2020) (47)
- Two independent receptors allow selective target lysis by T cell clones (1983) (46)
- Half-life extension using serum albumin-binding DARPin® domains (2017) (45)
- Half-life extension using serum albumin-binding DARPin® domains (2017) (45)
- Folding of a designed simple ankyrin repeat protein (2004) (43)
- Folding of a designed simple ankyrin repeat protein (2004) (43)
- Targeting Extracellular Domains D4 and D7 of Vascular Endothelial Growth Factor Receptor 2 Reveals Allosteric Receptor Regulatory Sites (2012) (43)
- Idiotypic determinants on T-cell subpopulations (1979) (43)
- Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate (2017) (42)
- Induction of specific immune unresponsiveness using purified mixed leukocyte culture-activated T lymphoblasts as autoimmunogen. I. Demonstration of general validity as to species and histocompatibility barriers (1977) (42)
- Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate (2017) (42)
- CELL-BOUND RECEPTORS FOR ALLOANTIGENS ON NORMAL LYMPHOCYTES (1974) (41)
- Chloroplast thioredoxin mutants without active-site cysteines facilitate the reduction of the regulatory disulphide bridge on the γ-subunit of chloroplast ATP synthase (1999) (40)
- Localization of rabbit intestinal sucrase with ferritin-antibody conjugates. (1970) (39)
- Structure of wild-type Plk-1 kinase domain in complex with a selective DARPin. (2008) (38)
- T cell receptors with allo-major histocompatibility complex specificity from rat and mouse. Similarity of size, plasmin susceptibility, and localization of antigen-binding region (1981) (38)
- CELL-BOUND RECEPTORS FOR ALLOANTIGENS ON NORMAL LYMPHOCYTES (1974) (37)
- Hydrophobicity engineering to facilitate surface display of heterologous gene products on Staphylococcus xylosus. (1995) (37)
- Crystal structure of a consensus‐designed ankyrin repeat protein: Implications for stability (2006) (36)
- Inhibition of mixed leukocyte culture by anti‐idiotypic antibodies (1975) (36)
- Beyond Antibodies: The DARPin® Drug Platform (2020) (36)
- Flow cytometric quantification of surface-displayed recombinant receptors on staphylococci. (1997) (36)
- Beyond Antibodies: The DARPin® Drug Platform (2020) (36)
- Jacalin, a lectin with anti-HIV-1 properties, and HIV-1 gp120 envelope protein interact with distinct regions of the CD4 molecule. (1994) (36)
- CELLULAR RECEPTORS: BINDING OF RADIOACTIVELY LABELED ANTI-ALLOANTISERUM (1972) (35)
- Staphylococcal Protein A in Immunoferritin Techniques (1977) (33)
- Protein A in immunoperoxidase techniques. (1979) (33)
- Induction of specific immune unresponsiveness with purified mixed leukocyte culture-activated T lymphoblasts as autoimmunogen. II. An analysis of the effects measured at the cellular and serological levels (1978) (33)
- Chromosomal sequencing using a PCR-based biotin-capture method allowed isolation of the complete gene for the outer membrane protein A of Klebsiella pneumoniae. (1998) (32)
- Impaired Mitogen‐Induced Interferon‐γ Production in Rheumatoid Arthritis and Related Diseases (1988) (32)
- Subgroup specific protection of mice from respiratory syncytial virus infection with peptides encompassing the amino acid region 174-187 from the G glycoprotein: the role of cysteinyl residues in protection. (1997) (32)
- Surface display on staphylococci: a comparative study (1996) (31)
- Idiotype positive T cells visualized by autoradiography and electron microscopy. (1975) (31)
- Local Graft‐Versus‐Host‐Reaction in Mice Specifically Inhibited by Anti‐Receptor Antibodies (1975) (31)
- Development of Non-Pathogenic Staphylococci as Vaccine Delivery Vehicles (1997) (30)
- Idiotype‐Positive T Lymphocytess (1975) (29)
- DNA Polymerase I Is Essential for Growth ofMethylobacterium dichloromethanicum DM4 with Dichloromethane (2000) (29)
- Invasive behavior of mouse sarcoma cells is inhibited by blocking a 37,000-dalton plasma membrane glycoprotein with Fab fragments. (1984) (28)
- Modulation of Major Histocompatibility Complex (MHC) Expression by Interferons and Microbial Agents (1988) (27)
- Idiotypic, alloantigen-reactive T lymphocyte receptors and their use to induce specific transplantation tolerance. (1977) (27)
- ATPase Activity of a Highly Stable α3β3γ Subcomplex of Thermophilic F1 Can Be Regulated by the Introduced Regulatory Region of γ Subunit of Chloroplast F1 * (2000) (26)
- Correlation between specific cytolysis and expression of idiotypic receptors of allograft-infiltrating cells (1976) (26)
- Binding of purified, soluble major histocompatibility complex polypeptide chains onto isolated T-cell receptors. I. Reactivity against allo- and self-determinants (1979) (24)
- CD14 and CD11b mediate serum-independent binding to human monocytes of an acylpolygalactoside isolated from Klebsiella pneumoniae (1994) (23)
- Binding of a membrane proteoglycan from Klebsiella pneumoniae and its derivatives to human leukocytes. (1992) (22)
- Induction or elimination of tumor‐specific immunity against a chemically‐induced rat tumor using auto‐anti‐idiotypic immunity (1982) (22)
- Inverse regulation of F1-ATPase activity by a mutation at the regulatory region on the γ subunit of chloroplast ATP synthase (2000) (20)
- Highly potent anti-SARS-CoV-2 multi-DARPin therapeutic candidates (2020) (20)
- Monoclonal antibodies directed to human insulin‐like growth factor I (IGF I) (1982) (20)
- Highly potent anti-SARS-CoV-2 multi-DARPin therapeutic candidates (2020) (20)
- Synthesis of moenocinol (1986) (19)
- Characterization of a drug-targetable allosteric site regulating vascular endothelial growth factor signaling (2018) (19)
- Bacterial Lysates and Ribosomes as Inducers of Specific Immune Responses: a Comparative Study (1993) (19)
- Scintigraphy with J001X, a Klebsiella membrane glycolipid, for the early diagnosis of chronic berylliosis: results from an experimental model. (1992) (19)
- Studies of the invasiveness of the chemically induced mouse sarcoma FS9. I. monoclonal antibodies to a 37,000 dalton membrane glycoprotein inhibit invasion of fibroblasts in vitro (1984) (18)
- T‐Cell Receptor Idiotypes (1980) (18)
- Scintigraphy with J001 macrophage targeting glycolipopeptide. A new approach for sarcoidosis imaging. (1992) (18)
- Monoclonal antibodies as probes for Aedes aegypti trypsin (1988) (18)
- Acylation of the lipid A region of a Klebsiella pneumoniae LPS controls the alternative pathway activation of human complement. (1994) (17)
- Partial Characterization of Cell Surface Idiotypes on Alloantigen‐Activated T Lymphoblasts (1978) (17)
- Molecular dynamics study of the stabilities of consensus designed ankyrin repeat proteins (2006) (16)
- Allotypes of anti-alloantibodies. (1974) (16)
- Antiidiotype antibodies: induction of specific transplantation tolerance in adult animals. (1979) (15)
- MP0250, a VEGF and HGF neutralizing DARPin® molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models (2017) (14)
- Ribosome Display: In Vitro Selection of Protein-Protein Interactions (2006) (14)
- Studies on chemically induced rat tumors. II. Partial protection against syngeneic lethal tumors by cloned syngeneic cytotoxic T lymphocytes (1983) (13)
- First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors (2020) (13)
- The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants (2022) (13)
- The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants (2022) (13)
- Chloroplast thioredoxin mutants without active-site cysteines facilitate the reduction of the regulatory disulphide bridge on the gamma-subunit of chloroplast ATP synthase. (1999) (12)
- Studies of Monoclonal Antibodies Specific for Major Histocompatibility Complex Products of the Rat (1985) (12)
- Phase I Mp0112 Wet AMD Study: Results Of A Single Escalating Dose Study With DARPin® MP0112 In Wet AMD (2011) (12)
- Scintigraphic potentials of J001X acylated poly-galactoside for imaging inflammatory lesions in pigs. (1993) (11)
- Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants (2021) (11)
- Monocyte cytokine secretion induced by chemically‐defined derivatives of Klebsiella pneumoniae (1992) (11)
- Alloantigens Derived from Stimulator Cells and Bound onto M LC‐activated Rat T Lymphoblasts (1979) (11)
- Diagnostic screening of multiple antigen-antibody reactions in a new single assay on nitrocellulose: the line immunobinding assay (LIBA). (1989) (10)
- Impaired mitogen-induced interferon-gamma production in rheumatoid arthritis and related diseases. (1988) (10)
- Anti-alloantibodies: a de novo product. (1973) (9)
- Studies of Monoclonal Antibodies Specific for Major Histocompatibility Complex Products of the Rat (1985) (9)
- Abstract B25: First-in-human Phase I study to evaluate MP0250, a DARPin blocking HGF and VEGF, in patients with advanced solid tumors (2015) (9)
- A method to obtain large quantities of Toxoplasma gondii tachyzoites with extreme purity. (1993) (9)
- Activation of human monocyte chemiluminescence response by acylpoly(1,3)galactosides derived from Klebsiella pneumoniae (1992) (8)
- ATPase activity of a highly stable alpha(3)beta(3)gamma subcomplex of thermophilic F(1) can be regulated by the introduced regulatory region of gamma subunit of chloroplast F(1). (2000) (8)
- Cellular Location of ‘Liver‐Specific’ Antigen F (1986) (8)
- Role of acyl residues in polyclonal murine B cell activation by acylpoly(1,3)galactosides from Klebsiella pneumoniae. (1993) (8)
- Ribosomes as carriers for antigenic determinants of the surface of micro-organisms. (1992) (7)
- Immunohistochemical study of beta-endorphin and related peptides in the "invading cells" of the human neurohypophysis during ontogenesis and adulthood. (1980) (7)
- Idiotype-positive T lymphocytes. (1975) (7)
- Specific Suppression of MLC and CML by Anti‐Idiotypic Antibodies in the Mouse (1977) (7)
- Abstract OT1-03-02: MP0274-CP101: A phase 1, first-in-human, single-arm, multi-center, open-label, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors (2018) (7)
- Induction of Anti‐Alloantibodies by Alloantibody Fragments (1974) (6)
- Lymphoscintigraphy via the targeting of macrophages with 99mTc-J001X poly-galactoside in a model of pyogranulomas developed in sheep lymph nodes. (1995) (6)
- Scintigraphy with 99mTechnetium-J001X acylated polygalactoside in melanoma recurrence (1995) (6)
- Specific impaired alloreactivity of mice immunized with syngeneic MLCT-lymphoblasts using muramylpeptides as adjuvant. (1981) (5)
- Antibodies against Recognition Structures: Preferential Accumulation in Lymph Nodes Draining a Corresponding Skin Graft (1972) (5)
- [Prolonged renal graft survival induced by blood transfusion (author's transl)]. (1978) (5)
- Monoclonal Antibodies Specific for Sendai Virus (1986) (5)
- An immunoglobulin V gene polymorphism in the rat (1982) (4)
- Horror autotoxicus? (1978) (4)
- Pegylation of Abicipar Increases Vitreal Half-Life, Supporting a Potential for up to 3 Month Duration of Action in the Clinic (2018) (4)
- Some studies on idiotypes and anti-idiotypic reactions and receptors in anti-allo-MHC T-cell immunity. (1979) (4)
- Pegylation of Abicipar Increases Vitreal Half-Life, Supporting a Potential for up to 3 Month Duration of Action in the Clinic (2018) (4)
- GLYCOSYLIMIDATES. 8. SYNTHESIS OF 1-THIOGLYCOSIDES (1983) (4)
- Monoclonal Antibodies Specific for Sendai Virus I. Production and Characterization of Monoclonal Antibodies (1986) (4)
- Multispecific DARPin® therapeutics demonstrate very high potency against SARS-CoV-2 variants in vitro (2021) (4)
- Studies of Monoclonal Antibodies Specific for Major Histocompatibility Complex Products of the Rat (1986) (4)
- Single Ascending Doses of DARPin®, MP0112, Show Potential for Quarterly Dosing in DME (2011) (3)
- Abstract P4-12-30: A bivalent Her2 targeting DARPin with high efficacy against Her2-low and Her2-positive tumors (2013) (3)
- Use of donor-specific T-cell lines for monitoring of human allograft recipients. I. Demonstration of IgG binding to autologous TCL. (1986) (3)
- Studies of Monoclonal Antibodies Specific for Major Histocompatibility Complex Products of the Rat (1985) (3)
- Interim results from the completed first-in-human phase I dose escalation study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF, in patients with advanced solid tumors (2016) (3)
- Abstract 3752: Preclinical pharmacology of MP0310: A 4-1BB/FAP bispecific DARPin drug candidate promoting tumor-restricted T-cell costimulation (2018) (3)
- Phase I MP0112 Wet AMD Study Imaging Results: Darpin® MP0112 Shows Potential For Quarterly Dosing In Wet AMD (2011) (3)
- Binding to leukocytes and induction of TNF alpha production involve different sites within the lipid-A region of LPS-like molecules. (1994) (3)
- Representation of heavy but not light chain Ig idiotypes on T cell receptors for alloantigens. (1979) (3)
- Inverse regulation of F1-ATPase activity by a mutation at the regulatory region on the gamma subunit of chloroplast ATP synthase. (2000) (3)
- Studies on chemically induced tumors in rats: I. Heterogeneity of tumor cells and establishment of syngeneic, tumor-specific cytotoxic T cell clones (1983) (2)
- Cover Picture: Consensus Design of Repeat Proteins (ChemBioChem 2/2004) (2004) (2)
- IDIOTYPIC RECEPTORS FOR ALLOANTIGEN ON T CELLS (1974) (2)
- Cover Picture: Consensus Design of Repeat Proteins (ChemBioChem 2/2004) (2004) (2)
- Induction of specific transplantation tolerance via immunisation with donor-directed idiotype(s). (1981) (2)
- Abstract 3029: FAP-mediated tumor accumulation of a T-cell agonistic FAP/4-1BB DARPin drug candidate analyzed by SPECT/CT and quantitative biodistribution (2018) (2)
- INDUCTION OF SPECIFIC TRANSPLANTATION TOLERANCE VIA IMMUNIZATION WITH DONOR‐SPECIFIC IDIOTYPES * (1982) (2)
- Abstract CT149: MP0250, a VEGF- and HGF-blocking multi-DARPin drug candidate, in combination with tyrosine-kinase-inhibitors targeting EGFR-mutated NSCLC: Preclinical rationale and phase Ib/II study outline (2018) (1)
- 1041TiPMP0250 – a dual inhibitor of VEGF and HGF - plus bortezomib + dexamethasone in a phase 2 open-label, single-arm, multicenter trial in patients with refractory and relapsed multiple myeloma (RRMM) (2017) (1)
- Abstract 2273: Selection of first-in-human clinical dose range for the tumor-targeted 4-1BB agonist MP0310 (AMG 506) using a pharmacokinetic/pharmacodynamics modeling approach (2020) (1)
- Potency of bortezomib in combination with MP0250, a bispecific VEGF- and HGF-targeting darpin, in a preclinical multiple myeloma model. (2014) (1)
- Breaking New Therapeutic Grounds: Fusion Proteins of Darpins and Other Nonantibody Binding Proteins (2013) (1)
- Abstract 4552: Tumor-restricted immune modulation by multispecific molecules from the DARPin toolbox (2018) (1)
- Comparison of an FAP-targeted, CD137 activating DARPin drug candidate with a non-targeted, CD137 activating antibody in a human PBMC transplanted HT-29 mouse tumor model. (2017) (1)
- Crystal structure of a designed selected Ankyrin Repeat protein in complex with the Maltose Binding Protein (2004) (0)
- Scintigraphy withJOOlMacrophage Targeting Glycolipopeptide* A NewApproachfor Sarcoidosis Imaging (2017) (0)
- A method for improving the immunogenicity of an immunogenic composition or a hapten and use for the production of vaccines (1995) (0)
- Characterization of a drug-targetable allosteric site regulating vascular endothelial growth factor signaling (2018) (0)
- REACTIONS USING ANTI-IDIOTYPIC ANTIBODIES* (1978) (0)
- Recognition of antigens by T lymphocytes (1978) (0)
- Crystal structure of E3_19 a designed ankyrin repeat protein (2006) (0)
- carrier protein adjuvant effect, immunogenic complex containing it, their preparation process, and nucleotide sequence vaccine. (1995) (0)
- SANK E3_5: an artificial Ankyrin repeat protein (2003) (0)
- Designed ankyrin repeat protein libraries: a valuable new tool for the crystallization of biological macromolecules (2004) (0)
- IDIOTYPIC RECEPTORS FOR ANTIGEN ON T LYMPHOCYTES (1976) (0)
- Scintigraphy withJOO1X, aKlebsiella membrane glycolipid, fortheearly diagnosis ofchronic berylliosis: results froman experimental model (1992) (0)
- [Lymphocyte membrane receptors mediating recognition of antigens (author's transl)]. (1979) (0)
- [Conjugation of ferritin with anti-rabbit saccharase immunoglobulin G]. (1969) (0)
- Evaluation of possible interference of anti-inflammatory drugs upon scintigraphic imaging with macrophage targeting 99mTc-J001X: effects of methylprednisolone, dexamethasone, indomethacin and methotrexate. (1994) (0)
- carrier protein has adjuvant effect, immunogenic containing the complex, their preparation method, nucleotide sequence and vaccine (1994) (0)
- Antitumor activity of MP0250, a bispecific VEGF- and HGF-targeting darpin, in patient-derived xenograft models. (2014) (0)
- Crystal structure of VEGFR-2 domains 4-5 in complex with DARPin D4b (2018) (0)
- peptide fragment of G protein of respiratory syncytial virus, immunogenic agent, pharmaceutical composition containing it and preparation process. (1995) (0)
- Collections de protéines de répétition comportant des modules de répétition (2001) (0)
- Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications (2012) (0)
- Abstract 3645: Preclinical characterization of a multi-specific DARPin molecule targeting PD1 and VEGF (2017) (0)
- included collection of proteins with repetitive sequences themselves (repeat proteins), the repetitive sequence module (2001) (0)
- Inverse regulation of F 1 -ATPase activity by a mutation at the regulatory region on the c subunit of chloroplast ATP synthase (0)
- Inhibition Of Vascular Leakage And Choroidal Neovascularization Using Vegf-inhibiting Darpins In Rodents (2012) (0)
- 1130. Ensovibep antiviral activity in ambulatory patients with COVID-19 is independent of baseline anti-SARS-CoV-2 antibodies and exhibits minimal selective pressure – Results from the placebo-controlled EMPATHY trial (2022) (0)
- Crystal structure of Aminoglycoside Phosphotransferase APH(3')-IIIa in complex with the inhibitor AR_3a (2005) (0)
- Delipidated polysaccharide compound, its preparation, and composition containing the same (1991) (0)
- included collection of proteins with repetitive sequences themselves (repeat proteins), the repetitive sequence module (2001) (0)
- Preliminary biomarker and pharmacokinetic analysis from the completed dose escalation part of the first-in-human Phase I study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF-A, in patients with advanced solid tumors (2016) (0)
- activity carrier protein with adjuvant containing them immunogenic complex, their manufacture, nucleotide sequence and vaccine (1995) (0)
- [Recognition of antigens by T-cells (author's transl)]. (1978) (0)
- Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A (2013) (0)
- Element immunogen, immunogenic agent, pharmaceutical composition and method of preparation. (1994) (0)
- Regulation of transplantation immune reactions by anti-idiotypic immunity: a new approach to achieve specific transplantation tolerance in man? (1977) (0)
- GLYCOSYL IMIDATES, 10. GLYCOSYL PHOSPHATES FROM GLYCOSYL TRICHLOROACETIMIDATES (1984) (0)
- of the G protein of respiratory syncytial virus production process, immunogenic compound, and pharmaceutical composition containing it, and peptide fragment (1995) (0)
- SPECIFIC AUTO-IMMUNITY DURING THE IMMUNE RESPONSE: IDIOTYPES AND ANTIGEN-BINDING SPECIFICITY OF ANTI-BODIES AND T CELL RECEPTORS (1979) (0)
- IDENTIFICATION OF AMINO ACID RESIDUES ON THE γ SUBUNIT RESPONSIBLE FOR THE REGULATION OF CHLOROPLAST ATP SYNTHASE (1999) (0)
- an obtaining process derived peptide respiratory syncytial virus, polypeptide, and expressing the bacterium, and their applications as medicaments (1994) (0)
- Collections de protéines de répétition comportant des modules de répétition (2001) (0)
- s6.m20.o5 Designed Ankyrin Repeat Protein Libraries: A Valuable new Tool for the Crystallization of Biological (2004) (0)
- CHARACTERISTICS OF IDIOTYPE-POSITIVE T LYMPHOCYTES AND THE USE OF ANTI-IDIOTYPIC ANTIBODIES TO SELECTIVELY INHIBIT T CELL FUNCTION (1976) (0)
- Local inhibition of IL-4 and IL-13 protects lung function in OVA mouse model (2011) (0)
- SANK E3_5: an artificial Ankyrin repeat protein (2003) (0)
- Synthesis of Moenocinol. (1987) (0)
- Crystal structure of a designed selected Ankyrin Repeat protein in complex with the Maltose Binding Protein (2004) (0)
- Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications (2012) (0)
- REDOX CASCADE IN CHLOROPLAST : REGULATION OF THIOL ENZYMES (2001) (0)
- Phage display by co-translational translocation fusion polypeptide. (2006) (0)
- Ensovibep, a SARS-CoV-2 antiviral DARPin, is safe and well tolerated in healthy volunteers: results of a first-in-human, ascending single-dose Phase 1 study. (2023) (0)
- Designed ankyrin repeat protein libraries: a valuable new tool for the crystallization of biological macromolecules (2004) (0)
- Induction of human monocyte chemiluminescence response by an acylated peptidopolygalactose (APPG) from Klebsiella pneumoniae: A role for complement receptor type three (CR3, CD11b/CD18) (1991) (0)
- Recognition of allo-MHC antigens in the self-MHC context. (1982) (0)
- Induction of specific unresponsiveness to transplantation antigens. (1977) (0)
- Immunogenic complex, its use, and method of preparing the vaccine containing (1996) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Hans Kaspar Binz?
Hans Kaspar Binz is affiliated with the following schools:
